



## OncoSil Medical Ltd Company Profile

### Overview

OncoSil Medical Ltd (ASX: OSL) is an Australian medical device company focused on developing localised treatments for patients living with pancreatic and liver cancer.

The Company has successfully developed a patented device, called OncoSil™, and is on track with its anticipated global commercialisation; the device is currently under clinical trial in leading sites around the world to receive the respective CE certification, and FDA and TGA approvals.

As a brachytherapy device, OncoSil™ is implanted directly into pancreatic and primary liver tumours.

Led by Daniel Kenny, the corporate leadership for OncoSil Medical Ltd is a multi-talented group of professionals with many years of successful global drug and device development.

### Speaker Profile

#### Mr. Daniel Kenny, CEO and Managing Director



**Mr. Daniel Kenny**, CEO and Managing Director joined OncoSil Medical in January 2015, with 30 years' experience in the Global Pharmaceutical and Medical Device Industry.

Daniel is an accomplished and proven biopharmaceutical business leader and, throughout his career, he has developed and successfully driven business with industry leaders such as Roche, Allergan and Baxter working in Australia, EMEA and the US.

Prior to joining OncoSil Medical, Daniel held the position of Chief Commercial Officer at ABIVAX a Paris based global biopharmaceutical company specialising in the development of novel vaccines and anti-virals.

*continued...*



At Baxter, Daniel served as Global Franchise Head Vaccines overseeing all Franchise Operations. Before this role, Daniel served as Vice President Baxter BioScience, EMEA and was responsible for all marketing and key business programmes in support of regional sales exceeding \$2.0bio.

Daniel also served with Roche as Global LifeCycle Leader for Roaccutance, a product generating sales in excess of CHF \$1.1bio (2002), assuming responsibility for all global strategic marketing and business development activities. Prior to this role, he was International Medical Manager and Medical Science and Safety Team leader responsible for post NDA clinical development strategy and critical issue work ups for regulatory authorities.

Prior to joining the pharmaceutical industry, Daniel completed over 10 years in clinical research in the fields of Ophthalmology with the Royal Australian College of Ophthalmologists and the University of Sydney and HIV/AIDS research at the University of New South Wales, Sydney.

Daniel is a graduate in Physics from the University of New South Wales and has completed business studies at both INSEAD and London Business School. He is also a graduate of the Australian Institute of Physics and is a member of the Australian Institute of Company Directors.

For further information, please visit: [onconsil.com.au](http://onconsil.com.au)